Biosimilars offer the promise of cutting edge treatments, but possibly at lower costs. With society pushing for therapies leading to a cure, can these new class of drugs help answer some of cancer’s most challenging problems?
Nearly 16,000 American kids are diagnosed with cancer annually. But only four percent of federal cancer research dollars is allotted to childhood cancer. What are the stories of these patients and how do they fit into the broader fight against cancer nationwide?
Drawing from leading thinkers across the country, in combination with Boston's revered medical community, The Atlantic will uncover the stories of patients and families, experts and professionals to explore the state and future of health care.